Neurodegenerative Diseases
-
Valeo Pharma Impresses Again with 210% Quarterly Year-over-Year Revenue Growth
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”) just released their FQ1/2023 earnings results and impressed again.…
-
Steve Saviuk of Valeo Pharma talks about revenue growth following impressive market gains
In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Steve Saviuk of Valeo Pharma on record 2021 revenues, achieving breakeven in 2022, and uplisting on the TSX
In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB:…
-
Valeo Pharma is cashed up and ready to expand as COVID restrictions end
Are we starting to see the beginning of the end of COVID’s reign of terror over humanity? I…
-
XPhyto Therapeutics is looking to hit a home run with their innovative medical products and therapies
New therapies and diagnostics in the pharmaceutical and medical industries can be a very lucrative area. To be…
-
Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio
COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a…
-
Valeo Pharma on a significant upswing with recent Health Canada approvals
In a new InvestorIntel interview Peter Clausi speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
